You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EBV

Showing 26 - 50 of 793
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

EBV Emia and EBV Positive PTLD After Allogenic HSCT Trial in Sanhe (EBV-TCR-T cells)

Completed
  • EBV Emia and EBV Positive PTLD After Allogenic HSCT
  • EBV-TCR-T cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Mar 6, 2022

Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder Trial in United States (cytotoxic t-lymphocytes)

Recruiting
  • Epstein-Barr Virus Infections
  • Primary Immune Deficiency Disorder
  • cytotoxic t-lymphocytes
  • Los Angeles, California
  • +7 more
Sep 27, 2022

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus Trial in Houston (MABEL CTLs, Cyclophosphamide,

Recruiting
  • Hodgkin Disease
  • +5 more
  • MABEL CTLs
  • +2 more
  • Houston, Texas
  • +1 more
Jan 13, 2023

Serologically Active Adult Systemic Lupus Erythematosus Trial in Nantes, Paris (Autologous EBV specific CTL infusion)

Terminated
  • Serologically Active Adult Systemic Lupus Erythematosus
  • Autologous EBV specific CTL infusion
  • Nantes, France
  • +2 more
Mar 24, 2022

Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma Trial in Singapore (FDG-PET, Galium-68 DOTATATE)

Recruiting
  • Nasopharyngeal Cancer
  • Epstein-Barr Virus Related Carcinoma
  • FDG-PET
  • Galium-68 DOTATATE
  • Singapore, Singapore
    National Cancer Centre Singapore
Oct 13, 2022

EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma Trial in Korea,

Recruiting
  • EBV Associated Extranodal NK/T-cell Lymphoma
  • EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
  • EBViNT Cell
  • Seoul, Gangnam-gu, Korea, Republic of
  • +7 more
Jul 7, 2022

Extranodal NK/T-cell Lymphoma Trial in Korea, Republic of (VT-EBV-N, Placebo)

Recruiting
  • Extranodal NK/T-cell Lymphoma
  • VT-EBV-N
  • Placebo
  • Busan, Korea, Republic of
  • +7 more
Apr 28, 2022

Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma Trial in Worldwide (Nanatinostat,

Recruiting
  • Nasopharyngeal Carcinoma
  • +4 more
  • Lynwood, California
  • +20 more
Jul 27, 2022

EBV-Related Hodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Non-Hodgkin's Lymphoma Trial in Houston (Dose Level 1A:

Not yet recruiting
  • EBV-Related Hodgkin Lymphoma
  • +2 more
  • Dose Level 1A: 2 x 10^7 cells/m2
  • +4 more
  • Houston, Texas
  • +1 more
Feb 7, 2022

Gastric Cancer Trial in Seoul (Antiviral treatment in combination with low-dose gemcitabine)

Not yet recruiting
  • Gastric Cancer
  • Antiviral treatment in combination with low-dose gemcitabine
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jun 21, 2022

Pulmonary Emphysema Trial in Heidelberg (EBV implantation, IBV implantation)

Completed
  • Pulmonary Emphysema
  • EBV implantation
  • IBV implantation
  • Heidelberg, Germany
    Thoraxklinik Heidelberg
Jul 4, 2022

Nasopharyngeal Carcinoma Trial in Zhongshan, Wuzhou (Blood and saliva, P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA, Fiberoptic

Recruiting
  • Nasopharyngeal Carcinoma
  • Blood and saliva
  • +2 more
  • Zhongshan, Guangdong, China
  • +1 more
Jul 20, 2022

Post-transplant Lymphoproliferative Disease, Transplant-Related Hematologic Malignancy Trial in London (Autologous EBV-CTL

Active, not recruiting
  • Post-transplant Lymphoproliferative Disease
  • Transplant-Related Hematologic Malignancy
  • Autologous EBV-CTL transduced with vector SFG-CNA12
  • +2 more
  • London, United Kingdom
  • +1 more
Jan 19, 2022

Epstein-Barr Virus Infections, Post-Transplant Lymphoproliferative Disorder, Lymphoma Trial in Montreal (Group A, Group B)

Recruiting
  • Epstein-Barr Virus Infections
  • +2 more
  • Group A
  • Group B
  • Montreal, Quebec, Canada
    Hôpital Maisonneuve-Rosemont
Apr 5, 2022

Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection Trial in Beijing (Rituximab

Recruiting
  • Secondary Hemophagocytic Lymphohistiocytosis
  • Chronic Active Epstein-Barr Virus Infection
  • Rituximab Monotherapy
  • Beijing, China
    Zhao Wang
May 18, 2022

Acute Lymphocytic Leukemia, Lymphoma Trial in New York (Biological/Genetically Modified T cells, Cyclophosphamide-based chemo)

Active, not recruiting
  • Acute Lymphocytic Leukemia
  • Lymphoma
  • Biological/Genetically Modified T cells
  • Cyclophosphamide-based chemotherapy
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 3, 2023

Epstein-Barr Virus Infections Trial in Strasbourg (Rituximab, control group)

Recruiting
  • Epstein-Barr Virus Infections
  • Strasbourg, France
    Les Hôpitaux Universitaires de Strasbourg
Dec 7, 2021

Epstein Barr Virus Infection in Radiologically Isolated Syndrome

Recruiting
  • Multiple Sclerosis
  • +2 more
  • NO INTERVENTION
  • Nice, France
    Nice University Hospital
Apr 3, 2023

Segmental Resection Combined With DEP Regimen for EBV-HLH

Not yet recruiting
  • Hemophagocytic Lymphohistiocytosis
  • +2 more
  • Segmental bowel resection combined with the DEP regimen
  • Beijing, Beijing, China
    Zhao Wang
Nov 9, 2023

Hemophagocytic Lymphohistiocytosis Trial in Beijing (L-DEP and PD-1 antibody)

Not yet recruiting
  • Hemophagocytic Lymphohistiocytosis
  • L-DEP and PD-1 antibody
  • Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Apr 19, 2022

Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Trial in Houston (autologous CAR.CD30 EBV specific-CTLs)

Active, not recruiting
  • Hodgkin's Lymphoma
  • Non-Hodgkin's Lymphoma
  • autologous CAR.CD30 EBV specific-CTLs
  • Houston, Texas
  • +1 more
Feb 4, 2022

EBV Infection Trial in Beijing (PD1 antibody, lenalidomide)

Recruiting
  • EBV Infection
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Jan 4, 2022

Occurrence of Antibodies Cross-reacting With Autoantigens in

Recruiting
  • Epstein-Barr Virus (EBV) Infection
  • Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments)
  • +2 more
  • Basel, Switzerland
    University Hospital Basel, Division of Internal Medicine
Nov 8, 2021

Neuroblastoma Trial in Houston (EBV specific CTLs)

Active, not recruiting
  • Neuroblastoma
  • EBV specific CTLs
  • Houston, Texas
    Texas Children's Hospital
Feb 2, 2022